Summary
This prediction ended on 03.10.16 with a price of €5.05. With a performance of 60.32% the BUY prediction by DirectorDealer was a big success. DirectorDealer has a follow-up prediction for Evotec SE where he still thinks Evotec SE is a Buy. DirectorDealer has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Evotec SE | -6.401% | -6.401% | -65.782% | -84.815% |
iShares Core DAX® | -1.958% | 4.037% | 23.702% | 22.534% |
iShares Nasdaq 100 | 0.272% | 8.670% | 28.181% | 41.859% |
iShares Nikkei 225® | 0.377% | 7.232% | 21.118% | 9.739% |
iShares S&P 500 | 0.370% | 6.511% | 29.221% | 41.850% |
Comments by DirectorDealer for this prediction
In the thread Evotec AG diskutieren
Director Dealing: Kauf
Director Dealing / Insider Kauf von Lanthaler, Dr. Werner (Aufsichtsorgan)
- Handelstag: 29.03.16
- Volumen: 61446 €
- Meldender: Lanthaler, Dr. Werner
Wir werten alle Insider Käufe aus. Dabei werden die größten Insiderkäufe und Verkäufe automatisch als Einschätzung angelegt. Mehr Informationen findest du im Profil von DirectorDealer.